Driven by Compassion


About Us

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.

Our Pipeline

Our pipeline emphasizes high value potential first-in-class biologics focused on dysregulated inflammation.

Our Assets

Avalo’s lead asset is AVTX-009,
an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).